M. G. Matera (Naples, Italy), I. Hall (Nottingham, United Kingdom)
Salt chamber treatment does not affect induced sputum inflammatory markers in asthma patients treated with inhaled steroids
J. Hedman, J. Sandell, K. Saarinen, T. Haahtela (Lappeenranta, Joutseno, Helsinki, Finland)
|  |
Osteoporosis in patients with long-term inhaled corticosteroids treatment
Z. Stojanovski, J. Minov, B. Janackov, D. Andjelkovic, G. Lozankovski, A. Lazerevska (Skopje, Fyrom)
| |
Selenium add-on therapy in bronchial asthma patients
J. Voicehovska, G. Orlikov, A. Skesters, A. Ivanovs, A. Silova, I. Baidekalne, N. Voicehovskis, J. Karpovs, E. Maulins (Riga, Latvia)
| |
Comparision of patient acceptability and clinical efficacy of different inhaler devices in asthmatics
P. Gurumurthy, S. Ranganath, S. Thomas, A. Holla, M. Padukudru (Mysore, India)
|  |
Reduction of asthma mortality in Salvador – Brazil, a remarkable early outcome of ProAR, a public health program for asthma control targeting severe asthmatics
C. Souza-Machado, A. Souza-Machado, E. Fonte, R. Franco, A. A. Cruz (Salvador, Bahia, Brazil)
| |
Comparison of a combination of HFA propelled fluticasone 125 mcg and salmeterol 25 mcg (FP + SM 125/25) with two separate single preparation pMDIs
P. Mahesh, P. Niphadkar, K. Gowrinath, V. Saini, A. M. Mesquita, C. J. Po, S. M. Purandare, A. Sule, P. Kotnis, J. A. Gogtay (Mysore, Mumbai, Manipal, Chandigarh, Goa, India)
| |
Potential causes of lack of control in severe asthma
K. Serban, M. Lazar, A. Croitoru, C. Toma, C. Tudose, S. Dumitrache-Rujinski, M. Bogdan, D. Bumbacea (Bucharest, Romania)
| |
Oral montelukast in patients with acute severe asthma
C. Ramsay, D. Pearson, A. Wilson (Norwich, United Kingdom)
| |
A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma
M. Filipovic, S. Cekic (Nis, Serbia And Montenegro)
| |
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
E. Bacci, F. Novelli, M. L. Bartoli, E. Masino, F. Dente, A. Di Franco, B. Vagaggini, P. Paggiaro (Pisa, Italy)
| |
Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma
V. Zugic, P. Rebic, N. Mujovic (Belgrade, Serbia And Montenegro)
| |
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations
M. Peters, J. Bousquet (Concord, Australia; Montpellier, France)
| |
Risk factors for psychological status in mild asthma: a cross-sectional survey
G. Wang, M. Chen, Y. R. Yuan, T. L. He, Z. L. Wang (Chengdu, China)
| |
Reduction of inhaled corticosteroids in asthmatic children
Z. Paunovic (Nis, Serbia And Montenegro)
| |
Tiotropium in severe asthma: an open label review of clinical efficacy
F. Brims, C. Fehrenbach, A. Chauhan (Portsmouth, United Kingdom)
| |
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma
R. Louis, G. Joos, A. Michiels, G. Vandenhoven, I. De Schepper, V. Duquenne, M. Noppen (Liege, Ghent, Brussels, Belgium)
| |
The dynamics of blood plasma antioxidant activity in patients with asthma exacerbation during the course of Phosphogliv admission
A. V. Lisitsa, S. K. Soodaeva, I. A. Klimanov, A. G. Chuchalin (Moscow, Russian Federation)
| |
A multicenter, open-label, randomized comparison of the effects of HFA-BDP and FP on asthmatic inflammation of lower airways and health-related quality of life
H. Ohbayashi, M. Adachi, M. Ichinose, K. Ohta, F. Kokubu, G. Tamura, Y. Tohda, K. Hirata, H. Yasuba (Mizunami City, Gifu Pref., Tokyo, Wakayama Pref., Miyagi Pref., Osaka, Japan)
| |
Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use?
R. Buhl, P. Kuna (Mainz, Germany; Lodz, Poland)
| |
The respiratory center reactivity in animal asthma model induced by sulfur hexafluoride (SF6-O2) breathing
Z. Donina, A. Storozhevykh (St. Petersburg, Russian Federation)
| |